Products list

Dosage forms and strengths

Solution for intravenous injection and oral administration
50, 100, 150, 200, 300 MBq on the specified date and time of delivery.

Indications for use
Determination of the functional state and visualization of the thyroid gland b using radiometry and scintigraphy.

Contraindications
Pregnancy, breastfeeding, as well as severe leukopenia and hypersensitivity.
General clinical contraindications to radionuclide studies.
Age limit up to 18 years.

Dosage and administration
Intravenously or orally. On an empty stomach the patient is given 0.185 - 0.370 MBq of the drug, dissolved in 30 - 50 ml of water, supplementing the administration with rinsing of the medicine from the walls of the used dishes.

Radiometry of the thyroid gland is carried out after 2, 4 and 24 hours. To conduct gammatopographic studies, the patient is given 8.0 - 10.0 MBq of the drug on an empty stomach or administered intravenously. The optimal time for scanning the thyroid gland is from 2 to 6 hours after administration of the drug.

Registration certificate
LS-001624

Best before date
60 hours from date and time of manufacture

Dosage forms and strengths
Solution for intravenous administration
100, 150, 300 MBq on the specified date and time of delivery.

Indications for use
Adults:
localization of the primary tumor and its metastases, assessment of the effectiveness of treatment and detection of relapses in patients with: pheochromocytoma and paraganglioma; carcinoids of the small intestine and lung; medullary thyroid cancer; neuroblastoma; Merkel cell tumors; diagnosis of disorders of the sympathetic innervation of the myocardium during myocardial infarction, arrhythmias, chronic heart failure, cardiomyopathies of various origins (including diabetic, ischemic and stress damage of the myocardium).

Pediatricks:
confirmation of the sympathoadrenal nature of the tumor in neuroblastoma, pheochromocytoma and ganglioneuroma; staging of the tumor process; assessment of the radicality of surgical treatment of the primary tumor; assessment of the effectiveness of chemotherapy for neuroblastoma, especially in patients with stages IV and IV; observation after treatment for timely detection of subclinical relapses of neuroblastoma and dissemination in the bone marrow.

Contraindications
Pregnancy, breastfeeding period. General clinical contraindications to radionuclide studies. Hypersensitivity.

Dosage and administration
The drug is administered intravenously. Recommended single doses: adults and children - 4 MBq/kg of body weight.

Registration certificate
P N003220/01

Best before date
30 hours from date and time of manufacture

Dosage forms and strengths

Solution for intravenous administration
150 MBq on the specified delivery date.

Indications for use
As an alternative method or adjunct to external beam therapy for the treatment of pain in bone metastases of malignant tumors that tend to metastasize to the skeleton: hormone-resistant forms of prostate and breast cancer, colon, lung, thyroid, uterine, kidney and skin.

Contraindications
Hypersensitivity to strontium and other components of the drug, previous therapy with strontium-89 (less than 3 months), patients with a short life expectancy (less than 3 months), spinal cord compression (due to metastatic lesions), the need for urgent surgical treatment, suppression of bone marrow hematopoiesis (thrombocytopenia - platelets less than 100 thousand/µl, anemia - hemoglobin less than 90 g/l, leukopenia - leukocytes less than 3 thousand/µl.)

Directions for use and doses
The drug is administered intravenously, slowly, over 1 - 2 minutes. The interval between courses is 12 weeks.

Registration certificate
P N001377/01

Best before date
30 days from the date of manufacture

Dosage forms and strengths
Oral solution
120, 200, 400, 600, 1000, 2000 MBq on the specified delivery date.

Indications for use
Assessment of the functional state of the thyroid gland, scanning and scintigraphy of the thyroid gland for various diseases, including the diagnosis of dysfunction of the thyroid gland, as well as A-cell thyroid cancer and metastases.


Contraindications
Pregnancy, breastfeeding, hypersensitivity.
Age limit: up to 18 years (diagnosis), up to 20 years (therapy).

Radiopharmaceutical diagnostic agent


Dosage and administration

When scanning the thyroid gland, determining protein-bound iodine and studying the whole body using radiometry, 0.06 - 0.60 MBq of the drug is administered.

Radiopharmaceutical therapeutic agent

Indications for use
Thyrotoxicosis and metastases of thyroid cancer.

Dosage and administration
For the treatment of differentiated thyroid cancer, as well as distant metastases, the dose is calculated: 37 - 56 MBq per kilogram of body weight.
For the treatment of thyrotoxicosis in diffuse and multinodular toxic goiter, the dose is selected individually in the range from 111 to 555 MBq.


Registration certificate
P N002167/01

Best before date
15 days from the date of manufacture

Dosage forms and strengths
Capsules
0.5; 1.0; 2.0; 4.0 GBq on the certain delivery date

Indications for use
The drug is used for the treatment of thyrotoxicosis in diffuse and multinodular toxic goiter, as well as for the treatment of thyroid cancer and its metastases.

Storage conditions
At temperatures from 15 to 25 °C in accordance with the current “Basic Sanitary
rules for ensuring radiation safety" (99/2010).


Registration certificate
LSR-003509/07

Best before date
20 days from the date of manufacture

Dosage forms and strengths
Substance-solution
No more than 700 GBq on the specified date and time of delivery.

Registration certificate
No. FS-2 065, date of inclusion in the register of medicines for medical use 08/27/2020.

Use
For the production and manufacture of radiopharmaceutical drugs in the form of sterile and non-sterile dosage forms.

Registration certificate
No. FS-002065

Best before date
15 days from the date of manufactures

Dosage forms and strengths

Capsules of the same denomination with an activity of 0.2; 0.4; 1.0; 4.0 MBq in quantities of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 pieces on the specified delivery date.

Indications for use
The drug is used by adults for assessment of the functional state of the thyroid gland, for scanning and scintigraphy of the thyroid gland for various diseases, including diagnosing dysfunction of the thyroid gland.

Contraindications
Pregnancy, breastfeeding, patients with swallowing disorders.

Dosage and administration
For oral administration. To study the functions of the thyroid gland by the amount of iodine-131 accumulation, during scintigraphy (scanning) of the thyroid gland, determination of protein-bound iodine and study of the peripheral stage of thyroid hormone metabolism using whole body radiometry, it is enough to get from 0.06 to 0.60 MBq.


Registration certificate
P N003388/01

Best before date


20 days from the date of manufacture

Dosage forms and strengths
Substance-solution
Not less than 370 MBq on the specified date and time of delivery.

Registration certificate
No. FS-001869, date of inclusion in the register of medicines for medical use 03/27/2019.

Use
For the production and manufacture of radiopharmaceutical drugs (RPPs) in the form of sterile dosage forms for parenteral use.


Best before date
10 days from the date and time of manufacture

Dosage forms and strengths
Extraction solution for RPPs preparation
1.0; 2.0; 3.0; 6.0 GBq on the specified date and time of delivery.

Registration certificate
No. FS-00452, date of inclusion in the register of medicines for medical use 12/07/2012.


Best before date
24 hours from production date and time

Номинал фасовок
50, 100, 150, 200, 250, 300, 500, 1000 МБк на установленную дату и время поставки.

Dosage forms and strengths
Solution for intravenous administration
50, 100, 150, 200, 250, 300, 500, 1000 MBq on the specified delivery date and time.

Indications for use
The drug is used in adults and children for:

• determination of effective renal blood flow (plasma flow);
• studies of the total and separate secretory and excretory capacity of the kidneys and urodynamics of the upper and lower urinary tract;
• assessment of the anatomical features and topography of the kidneys and urinary tract;
• identifying dysfunctions of the kidneys and urinary tract, determining the degree of these disorders in various diseases (acute and chronic pyelonephritis, urolithiasis, renovascular hypertension, neoplasms of the bladder and prostate).


Contraindications
Pregnancy, breastfeeding, as well as severe leukopenia and hypersensitivity. Children's age up to 1 year.


Registration certificate
P N002366/01

Best before date
48 hours from production date and time

Dosage forms and strengths
Solution for intravenous administration
20, 40, 80, 200 MBq on the specified delivery date.

Indications for use
Used in adults for:

• determination of effective renal blood flow (plasma flow);
• studies of total and separate secretory and excretory functions of the kidneys and urodynamics of the upper and lower urinary tract;
• assessment of anatomical features and topography of the kidneys;
• identifying dysfunctions of the kidneys and urinary tract, determining the degree of these disorders in various diseases (renovascular hypertension, malignant tumors of the bladder and prostate gland).

Contraindications
Hypersensitivity to the drug and its components, pregnancy, lactation, leukopenia.
Age limit - up to 18 years.


Registration certificate
P N003391/01

Best before date
20 days from the date of manufacture

Dosage forms and strengths:
Capsules
10 or 15 capsules with an activity of 30 kBq on the certain delivery date.

Indications for use:
It is recommended to use it as a screening method for detecting breast pathology.

Contraindications:
In patients with swallowing disorders. Pregnancy, breastfeeding, under the age of 18 years.

Directions for use and dosage:
24 hours before the examination, the patient takes one capsule with an activity of 30 kBq on an empty stomach.

Registration certificate
LSR-009614/09.

Best before date:
30 days from the date of manufacture.

Dosage forms and strengths
Solution for intravenous administration.
40, 80, 200, 400,1000 MBq on the specified delivery date.

Indications for use:
Determination of the life expectancy of erythrocytes, leukocytes and platelets in various hematological diseases. Determination of the volume of circulating and deposited red blood cells. Diagnosis of gastrointestinal bleeding.

Contraindications:
Pregnancy, breastfeeding. General clinical contraindications to radionuclide studies. Under the age of 18 years


Registration certificate
P N003219/01.


Best before date:
3 months from the date of manufacture.

Dosage forms and strengths
Solution for intravenous administration
400, 800 MBq on the specified delivery date.

Indications for use:
For the diagnosis of systemic malignant lymphoproliferative diseases (lymphogranulomatosis, Beck's sarcoidosis, etc.), primary and metastatic lung tumors, soft tissue sarcomas.

Contraindications:
Pregnancy, breastfeeding. The presence of hypersensitivity to the drug or its components.

Registration certificate
P N001744/01.


Best before date:
10 days from the date of manufacture.

Dosage forms and strengths
Solution for intravenous administration and oral administration
1.0; 1.5; 3.0; 5.0; 8.0; 10.0 GBq on the specified date and time of delivery.


Indications for use:
As a diagnostic tool for scintigraphy (scanning) of the thyroid and salivary glands; brain scintigraphy; radionuclide angiocardiography and ventriculography. For the preparation of various radiopharmaceuticals based on sets of appropriate reagents.

Contraindications:
General clinical contraindications to radionuclide studies. Pregnancy, breastfeeding within 24 hours after administration of the drug. Children under the age of 18


Registration certificate
LS-000197.

Best before date:
1) Sodium pertechnetate, 99mTc for the preparation of radiopharmaceuticals: with a volume activity of 74 MBq/ml - 1 hour; at higher volumetric activity - depending on its value, but not more than 24 hours, taking into account that the volumetric activity must be at least 74 MBq/ml - from the date and time of manufacture.
2) Sodium pertechnetate, 99mTc for diagnostic purposes with a volume activity of 74 MBq/ml - 12 hours, with a higher volume activity - depending on its value, taking into account that it must be at least 17 MBq/ml from the date and time manufacturing

Dosage forms and strengths
Solution for the preparation of radiopharmaceuticals for intravenous administration.
120, 240, 500,1000, 2000 MBq on the specified delivery date and time

Indications for use
For the preparation of radiopharmaceuticals for intravenous administration.

Registration certificate
LS-001953.

Best before date:
10 days from the date and time of manufacture.